News

GLP-1 race heats up: Where Eli Lilly stands after weak trial data

Eli Lilly's (LLY) recent earnings and GLP-1 trial results shook the biopharma market this week. Courtney Breen, Bernstein ...

Daily oral GLP-1 pill could be just as effective as weekly shots: Drugmaker

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 shots.

Can Eli Lilly keep its GLP-1 crown? Q2 earnings will tell

Eli Lilly (NYSE:LLY) is set to report Q2 earnings on Thursday, August 7, before the market opens, with Wall Street closely ...

Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Eli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

Eli Lilly raises 2025 revenue guidance to $60B-$62B while expanding GLP-1 pipeline and production

Q2 2025 Management View CEO David A. Ricks highlighted a strong quarter, stating, "Q2 was a strong quarter. We delivered robust revenue growth, shared top line clinical data from multiple Phase III ...
Fierce Pharma2d

Novo's outgoing CEO prepares to hand off business as sales threats from Lilly, GLP-1 compounders persist

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...